{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T22:29:21Z","timestamp":1790375361213,"version":"4.1.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["NHLBI HL167383"],"award-info":[{"award-number":["NHLBI HL167383"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["F30HL175876"],"award-info":[{"award-number":["F30HL175876"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["F30HL170641"],"award-info":[{"award-number":["F30HL170641"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"NCATS","doi-asserted-by":"publisher","award":["1K12TR004384"],"award-info":[{"award-number":["1K12TR004384"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","award":["F30HL175876"],"award-info":[{"award-number":["F30HL175876"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","award":["F30HL170641"],"award-info":[{"award-number":["F30HL170641"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","award":["F32HL165838"],"award-info":[{"award-number":["F32HL165838"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","award":["HL155078"],"award-info":[{"award-number":["HL155078"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Vessels, Thrombosis & Hemostasis"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.bvth.2025.100127","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T05:21:10Z","timestamp":1763616070000},"page":"100127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Distinct endothelial cell toxicities of Abl tyrosine kinase inhibitors lead to arterial thrombosis"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6839-4996","authenticated-orcid":false,"given":"Richard","family":"Travers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alec","family":"Stepanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiana","family":"Redford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole L.","family":"Svedberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn","family":"Merrill-Skoloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Flaumenhaft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris Z.","family":"Jaffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.bvth.2025.100127_bib1","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1002\/cncr.26679","article-title":"Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy","volume":"118","author":"Huang","year":"2012","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.bvth.2025.100127_bib2","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1001\/jamaoncol.2015.5932","article-title":"Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: a systematic review and meta-analysis","volume":"2","author":"Douxfils","year":"2016","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.bvth.2025.100127_bib3","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1056\/NEJMoa2400858","article-title":"Asciminib in newly diagnosed chronic myeloid leukemia","volume":"391","author":"Hochhaus","year":"2024","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.bvth.2025.100127_bib4","doi-asserted-by":"crossref","first-page":"e618","DOI":"10.1016\/S2352-3026(18)30176-5","article-title":"Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study","volume":"5","author":"Jabbour","year":"2018","journal-title":"Lancet Haematol"},{"issue":"6","key":"10.1016\/j.bvth.2025.100127_bib5","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1182\/blood.2024024851","article-title":"Shedding light on resistance to asciminib","volume":"144","author":"Breccia","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bvth.2025.100127_bib6","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/cam4.2687","article-title":"Varying effects of tyrosine kinase inhibitors on platelet function-A need for individualized CML treatment to minimize the risk for hemostatic and thrombotic complications?","volume":"9","author":"Deb","year":"2020","journal-title":"Cancer Med"},{"issue":"11","key":"10.1016\/j.bvth.2025.100127_bib7","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1002\/cncr.24257","article-title":"Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy","volume":"115","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.bvth.2025.100127_bib8","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1055\/s-0039-1688787","article-title":"Ponatinib tyrosine kinase inhibitor induces a thromboinflammatory response","volume":"119","author":"Hamadi","year":"2019","journal-title":"Thromb Haemost"},{"issue":"15","key":"10.1016\/j.bvth.2025.100127_bib9","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1182\/bloodadvances.2019000034","article-title":"Ponatinib treatment promotes arterial thrombosis and hyperactive platelets","volume":"3","author":"Merkulova","year":"2019","journal-title":"Blood Adv"},{"issue":"14","key":"10.1016\/j.bvth.2025.100127_bib10","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1182\/blood-2018-10-881557","article-title":"Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib","volume":"133","author":"Latifi","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bvth.2025.100127_bib11","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.thromres.2014.11.009","article-title":"The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear","volume":"135","author":"Loren","year":"2015","journal-title":"Thromb Res"},{"issue":"1","key":"10.1016\/j.bvth.2025.100127_bib12","doi-asserted-by":"crossref","DOI":"10.1124\/jpet.124.002104","article-title":"Pharmacological effects of small molecule BCR-ABL tyrosine kinase inhibitors on platelet function","volume":"392","author":"Zhang","year":"2025","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bvth.2025.100127_bib13","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.thromres.2016.07.019","article-title":"The tyrosine kinase inhibitor, nilotinib potentiates a prothrombotic state","volume":"145","author":"Alhawiti","year":"2016","journal-title":"Thromb Res"},{"key":"10.1016\/j.bvth.2025.100127_bib14","first-page":"46","article-title":"Effects of nilotinib on platelet function in patients with chronic myeloid leukemia in chronic phase","volume":"11","author":"Alqasim","year":"2019","journal-title":"Leuk Res Rep"},{"issue":"11","key":"10.1016\/j.bvth.2025.100127_bib15","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1161\/CIRCULATIONAHA.125.073610","article-title":"Ponatinib, but not the new Abl-kinase inhibitor asciminib, activates platelets, leukocytes, and endothelial cell TNF signaling to induce atherosclerotic plaque inflammation, myocardial infarction, and stroke","volume":"152","author":"Stepanian","year":"2025","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.bvth.2025.100127_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0294438","article-title":"Differential vascular endothelial cell toxicity of established and novel BCR-ABL tyrosine kinase inhibitors","volume":"18","author":"Wang","year":"2023","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.bvth.2025.100127_bib17","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1055\/s-0038-1624566","article-title":"BCR-ABL tyrosine kinase inhibitors: which mechanism(s) may explain the risk of thrombosis?","volume":"2","author":"Haguet","year":"2018","journal-title":"TH Open"},{"issue":"1","key":"10.1016\/j.bvth.2025.100127_bib18","doi-asserted-by":"crossref","DOI":"10.1080\/09537104.2022.2156492","article-title":"Platelet-derived microparticles stimulated by anti-\u03b22GPI\/\u03b22GPI complexes induce pyroptosis of endothelial cells in antiphospholipid syndrome","volume":"34","author":"Di","year":"2023","journal-title":"Platelets"},{"issue":"4","key":"10.1016\/j.bvth.2025.100127_bib19","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1161\/ATVBAHA.116.308126","article-title":"Activated platelets induce endothelial cell activation via an interleukin-1\u03b2 pathway in systemic lupus erythematosus","volume":"37","author":"Nhek","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"10.1016\/j.bvth.2025.100127_bib20","doi-asserted-by":"crossref","first-page":"e89012","DOI":"10.1371\/journal.pone.0089012","article-title":"Endothelial activation by platelets from sickle cell anemia patients","volume":"9","author":"Proen\u00e7a-Ferreira","year":"2014","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.bvth.2025.100127_bib21","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1080\/17474086.2022.2110061","article-title":"The role of platelets, neutrophils and endothelium in COVID-19 infection","volume":"15","author":"Falcinelli","year":"2022","journal-title":"Expert Rev Hematol"},{"issue":"12","key":"10.1016\/j.bvth.2025.100127_bib22","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1080\/10428194.2023.2242990","article-title":"High sensitivity c-reactive protein and circulating biomarkers of endothelial dysfunction in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors","volume":"64","author":"Aghel","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.bvth.2025.100127_bib23","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/10428194.2018.1466294","article-title":"Bosutinib, dasatinib, imatinib, nilotinib, and ponatinib differentially affect the vascular molecular pathways and functionality of human endothelial cells","volume":"60","author":"Gover-Proaktor","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"suppl 1","key":"10.1016\/j.bvth.2025.100127_bib24","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1182\/blood-2018-99-113568","article-title":"Prevalence of comorbidities relevant to the choice of second-generation (2-G) tyrosine kinase inhibitor (TKI) for the treatment of chronic myeloid leukemia (CML) in the United States using real-world claims databases","volume":"132","author":"Jabbour","year":"2018","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bvth.2025.100127_bib25","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.thromres.2011.10.010","article-title":"Platelet-leukocyte interactions in thrombosis","volume":"129","author":"Cerletti","year":"2012","journal-title":"Thromb Res"},{"issue":"2-3","key":"10.1016\/j.bvth.2025.100127_bib26","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0049-3848(02)00354-7","article-title":"Markers of platelet activation and platelet-leukocyte interaction in patients with myeloproliferative syndromes","volume":"108","author":"Villmow","year":"2002","journal-title":"Thromb Res"},{"issue":"24","key":"10.1016\/j.bvth.2025.100127_bib27","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","article-title":"Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure","volume":"381","author":"Hughes","year":"2019","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.bvth.2025.100127_bib28","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias","volume":"367","author":"Cortes","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bvth.2025.100127_bib29","first-page":"233","article-title":"Development and targeted use of nilotinib in chronic myeloid leukemia","volume":"2","author":"Fava","year":"2009","journal-title":"Drug Des Devel Ther"},{"issue":"8","key":"10.1016\/j.bvth.2025.100127_bib30","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.bvth.2025.100127_bib31","doi-asserted-by":"crossref","first-page":"6232","DOI":"10.1158\/1078-0432.CCR-09-0224","article-title":"Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors","volume":"15","author":"Demetri","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.bvth.2025.100127_bib32","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1161\/CIRCRESAHA.108.174235","article-title":"Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion","volume":"102","author":"Caprio","year":"2008","journal-title":"Circ Res"},{"issue":"4","key":"10.1016\/j.bvth.2025.100127_bib33","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.bvth.2025.100127_bib34","doi-asserted-by":"crossref","first-page":"4675","DOI":"10.1182\/blood-2010-05-283986","article-title":"Laser-induced endothelial cell activation supports fibrin formation","volume":"116","author":"Atkinson","year":"2010","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.bvth.2025.100127_bib35","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1182\/blood-2013-12-547208","article-title":"Both platelet- and endothelial cell-derived ERp5 support thrombus formation in a laser-induced mouse model of thrombosis","volume":"125","author":"Passam","year":"2015","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bvth.2025.100127_bib36","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1161\/CIRCULATIONAHA.125.073610","article-title":"Ponatinib, but not the new Abl-kinase inhibitor asciminib, activates platelets, leukocytes, and endothelial cell TNF signaling to induce atherosclerotic plaque inflammation, myocardial infarction, and stroke","volume":"152","author":"Stepanian","year":"2025","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.bvth.2025.100127_bib37","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1177\/0192623310378866","article-title":"Biomarkers of endothelial cell activation serve as potential surrogate markers for drug-induced vascular injury","volume":"38","author":"Zhang","year":"2010","journal-title":"Toxicol Pathol"},{"issue":"11","key":"10.1016\/j.bvth.2025.100127_bib38","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1038\/leu.2017.245","article-title":"Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site","volume":"31","author":"Hadzijusufovic","year":"2017","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.bvth.2025.100127_bib39","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/j.1538-7836.2011.04218.x","article-title":"Mechanisms underlying FeCl3-induced arterial thrombosis","volume":"9","author":"Eckly","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"5","key":"10.1016\/j.bvth.2025.100127_bib40","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1055\/s-0038-1653883","article-title":"Vessel wall injury and arterial thrombosis induced by a photochemical reaction","volume":"73","author":"Saniabadi","year":"1995","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1016\/j.bvth.2025.100127_bib41","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/j.1538-7836.2007.02443.x","article-title":"Increased platelet, leukocyte, and endothelial cell activity are associated with increased coagulability in patients after total knee arthroplasty","volume":"5","author":"Kageyama","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.bvth.2025.100127_bib42","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/jth.13911","article-title":"Inflammation and thrombosis: roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis","volume":"16","author":"Iba","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.bvth.2025.100127_bib43","first-page":"224","article-title":"Platelet-leucocyte aggregates as novel biomarkers in cardiovascular diseases","volume":"11","author":"Pluta","year":"2022","journal-title":"Biology (Basel)"},{"issue":"3","key":"10.1016\/j.bvth.2025.100127_bib44","doi-asserted-by":"crossref","first-page":"e12709","DOI":"10.1002\/rth2.12709","article-title":"Platelet-leukocyte interactions in COVID-19: contributions to hypercoagulability, inflammation, and disease severity","volume":"6","author":"Hottz","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"8","key":"10.1016\/j.bvth.2025.100127_bib45","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1080\/09537104.2022.2087867","article-title":"Platelet-leukocyte aggregate formation and inflammation in patients with pulmonary arterial hypertension and CTEPH","volume":"33","author":"\u00c5berg","year":"2022","journal-title":"Platelets"},{"issue":"9","key":"10.1016\/j.bvth.2025.100127_bib46","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1182\/blood-2009-02-205328","article-title":"The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo","volume":"114","author":"Gratacap","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bvth.2025.100127_bib47","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s12033-007-0072-7","article-title":"Cell adhesion molecules: potential therapeutic & diagnostic implications","volume":"38","author":"Mousa","year":"2008","journal-title":"Mol Biotechnol"},{"issue":"12","key":"10.1016\/j.bvth.2025.100127_bib48","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.tips.2003.10.004","article-title":"Leukocyte and endothelial cell adhesion molecules as targets for therapeutic interventions in inflammatory disease","volume":"24","author":"Ulbrich","year":"2003","journal-title":"Trends Pharmacol Sci"},{"issue":"12","key":"10.1016\/j.bvth.2025.100127_bib49","doi-asserted-by":"crossref","first-page":"e902","DOI":"10.1016\/S2352-3026(21)00333-1","article-title":"Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial","volume":"8","author":"Murai","year":"2021","journal-title":"Lancet Haematol"},{"issue":"5","key":"10.1016\/j.bvth.2025.100127_bib50","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s40261-018-0623-7","article-title":"Low-dose ponatinib in intolerant chronic myeloid leukemia patients: a safe and effective option","volume":"38","author":"Iurlo","year":"2018","journal-title":"Clin Drug Investig"},{"issue":"1","key":"10.1016\/j.bvth.2025.100127_bib51","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s40360-018-0270-x","article-title":"Preclinical pharmacokinetic evaluation to facilitate repurposing of tyrosine kinase inhibitors nilotinib and imatinib as antiviral agents","volume":"19","author":"Ananthula","year":"2018","journal-title":"BMC Pharmacol Toxicol"},{"issue":"14","key":"10.1016\/j.bvth.2025.100127_bib52","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1182\/bloodadvances.2018020396","article-title":"A phosphoproteomic signature in endothelial cells predicts vascular toxicity of tyrosine kinase inhibitors used in CML","volume":"2","author":"Gopal","year":"2018","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.bvth.2025.100127_bib53","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/s41375-025-02592-9","article-title":"Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: phase 1 study final results","volume":"39","author":"Cortes","year":"2025","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.bvth.2025.100127_bib54","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1182\/blood.2024025800","article-title":"Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia","volume":"145","author":"Luskin","year":"2025","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.bvth.2025.100127_bib55","doi-asserted-by":"crossref","first-page":"5116","DOI":"10.3390\/cancers13205116","article-title":"Which tyrosine kinase inhibitors should be selected as the first-line treatment for chronic myelogenous leukemia in chronic phase?","volume":"13","author":"Ono","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.bvth.2025.100127_bib56","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2024.5157","article-title":"Olverembatinib after failure of tyrosine kinase inhibitors, including ponatinib or asciminib: a phase 1b randomized clinical trial","volume":"11","author":"Jabbour","year":"2025","journal-title":"JAMA Oncol"}],"container-title":["Blood Vessels, Thrombosis & Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950327225000841?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950327225000841?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T13:36:46Z","timestamp":1778938606000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950327225000841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2950327225000841"],"URL":"https:\/\/doi.org\/10.1016\/j.bvth.2025.100127","relation":{},"ISSN":["2950-3272"],"issn-type":[{"value":"2950-3272","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Distinct endothelial cell toxicities of Abl tyrosine kinase inhibitors lead to arterial thrombosis","name":"articletitle","label":"Article Title"},{"value":"Blood Vessels, Thrombosis & Hemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bvth.2025.100127","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100127"}}